Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
grade D 26.25 -1.43% -0.38
ITCI closed down 1.43 percent on Friday, January 17, 2020, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ITCI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.43%
NR7 Range Contraction -1.43%
Inside Day Range Contraction -1.43%
Wide Bands Range Expansion -1.43%
Oversold Stochastic Weakness -1.43%
Fell Below 20 DMA Bearish -0.38%
Stochastic Reached Oversold Weakness -0.38%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
Medicine Biopharmaceutical Disorders Neuroscience Alzheimer's Disease Parkinson's Disease Schizophrenia Drug Development Psychiatry Psychiatric Diagnosis Treatment Of Parkinson's Disease Dementia Aging Associated Diseases Cognitive Disorders Human Diseases Major Depressive Disorders Bipolar Disorders Cardiovascular And Other Diseases Cognitive Dysfunction Cognitive Impairment Learning Disabilities

Is ITCI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 43.56
52 Week Low 6.75
Average Volume 3,310,097
200-Day Moving Average 12.44
50-Day Moving Average 17.68
20-Day Moving Average 28.81
10-Day Moving Average 27.21
Average True Range 2.33
ADX 44.31
+DI 35.45
-DI 18.47
Chandelier Exit (Long, 3 ATRs ) 36.56
Chandelier Exit (Short, 3 ATRs ) 19.18
Upper Bollinger Band 42.44
Lower Bollinger Band 15.17
Percent B (%b) 0.41
BandWidth 94.66
MACD Line 2.45
MACD Signal Line 3.61
MACD Histogram -1.1565
Fundamentals Value
Market Cap 1.14 Billion
Num Shares 43.4 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -11.12
Price-to-Sales 2144.19
Price-to-Book 1.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.74
Resistance 3 (R3) 27.87 27.50 27.49
Resistance 2 (R2) 27.50 27.13 27.44 27.40
Resistance 1 (R1) 26.88 26.89 26.70 26.75 27.32
Pivot Point 26.51 26.51 26.42 26.45 26.51
Support 1 (S1) 25.89 26.14 25.71 25.76 25.18
Support 2 (S2) 25.52 25.90 25.46 25.10
Support 3 (S3) 24.90 25.52 25.01
Support 4 (S4) 24.77